Evidence map›Paper›PMID 27267778›Full record

ArticleCancer immunology research2016

Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.

Ann Mary Joseph, Ratika Srivastava, Jovanny Zabaleta, Eduardo Davila

Open access · bronzeAbstract read
In one paragraph

Article in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Tumor-infiltrating CD8Drug discovery today · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ann Mary JosephUniversity of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland. Department of Microbiology and Immunology, University of Maryland, Baltimore, Maryland.
Ratika SrivastavaUniversity of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland.
Jovanny ZabaletaDepartment of Pediatrics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
Eduardo DavilaUniversity of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland. Department of Microbiology and Immunology, University of Maryland, Baltimore, Maryland. edavila@som.umaryland.edu.
Louisiana State University Health Sciences Center New Orleans · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Molecular and Soc. Determinants of Obesity and Metabolic Disorders in YouthU54MD008176 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BASKIN, MONICA L. · 2012 to 2016
$13.7M
Mentoring Translational Researchers in LouisianaP20GM103501 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2012 to 2014
$6.3M
Training CoreP20MD004817 · NIMHD · DILLARD UNIVERSITY · PI JONES, WARREN ALLEN · 2010 to 2014
$6.3M
Translational Genomics CoreP30GM114732 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2015 to 2019
$5.2M
Signaling Pathways in Innate ImmunityT32AI095190 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Stefanie N. Vogel · 2012 to 2026
$4.7M
IMMUNITY AND INFECTIONT32AI007540 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI KAPER, JAMES B · 1998 to 2018
$2.2M
TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of CostimulationR01CA140917 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI DAVILA, EDUARDO V · 2009 to 2013
$1.5M
NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA140917NIAID NIH HHS T32 AI007540NIAID NIH HHS T32 AI095190NIGMS NIH HHS P20 GM103501NIGMS NIH HHS P30 GM114732NIGMS NIH HHS U54 GM104940NIMHD NIH HHS P20 MD004817NIMHD NIH HHS U54 MD008176
6 · The paper itself

Abstract

The activation of TLR-MyD88 (Toll-like receptor-myeloid differentiation factor 88) signaling within T cells functions as a potent costimulatory signal that boosts antitumor and antiviral responses. However, the molecular mechanisms underlying the costimulatory processes are poorly understood. We compared microarray gene analysis data between TLR1-TLR2-stimulated and unstimulated T-cell receptor transgenic "pmel" and MyD88(-/-) pmel CD8(+) T cells and identified changes in the expression of several TNF family members. In particular, TLR stimulation increased 4-1BB levels in pmel but not in MyD88(-/-)pmel T cells. A link between 4-1BB and TLR1-TLR2 signaling in CD8(+) T cells was highlighted by the suboptimal responses of 4-1BB(-/-) T cells to TLR1-TLR2 agonist, but their normal response to CD28 or OX40 costimulation. Blocking 4-1BB signaling with antibodies also hindered the costimulatory effects of the TLR1-TLR2 agonist. The elevated levels of 4-1BB transcripts in TLR1-TLR2-stimulated cells were not due to increased mRNA stability nor increased histone activation, but instead were associated with increased binding of p65 and c-Jun to two distinct 4-1BB promoter sites. Combining TLR1-TLR2 ligand with an agonistic antibody to 4-1BB enhanced the antitumor activity in mice with established melanoma tumors. These studies reveal that the costimulatory effects of TLR1-TLR2 signaling in CD8(+) T cells are in part mediated by 4-1BB and are important for mounting an effective antitumor immune response. Cancer Immunol Res; 4(8); 708-16. ©2016 AACR.

Indexed as

Signal TransductionAnimalsCD8-Positive T-LymphocytesCell SurvivalCytotoxicity, ImmunologicGene ExpressionGene Expression ProfilingImmunomodulationMelanomaMelanoma, ExperimentalMiceMice, KnockoutMyeloid Differentiation Factor 88Promoter Regions, GeneticProtein BindingToll-Like Receptor 1Myeloid Differentiation Factor 88Toll-Like Receptor 1Toll-Like Receptor 2Transcription FactorsTumor Necrosis Factor-alphaTumor Necrosis Factor Receptor Superfamily, Member 9

Identifiers

PMID27267778
PMCPMC4970957
OpenAlexW2416729585

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.